Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHCPR GUIDELINE ON MANAGEMENT OF CANCER-RELATED

Executive Summary

AHCPR GUIDELINE ON MANAGEMENT OF CANCER-RELATED PAIN in clinical practice is currently targeted for release this autumn, HHS' Agency for Health Care Policy and Research said. The agency has 15 clinical practice guidelines on its schedule for dissemination in 1993 and 1994. Guidelines on the initial evaluation and early treatment of HIV-positive individuals, and on the treatment and diagnosis of benign prostatic hyperplasia are anticipated to be out this summer. Farthest along is a guide on sickle cell disease in newborns and infants, which is scheduled for release April 27. Among the documents to be unveiled in 1993 is a guideline for primary care physicians covering otitis media in children. There has been some debate about the effectiveness of current treatments for otitis media, which include antibiotics, tubal insertions and surgery. Critics of current treatment practices include Erdem Cantekin, PhD, University of Pittsburgh, while other experts defend the use of the therapies. The panel creating the otitis media guideline held a public hearing in May 1992 ("The Pink Sheet" June 1, 1992, T&G-14). Other guides targeted for release some time this year cover the care and evaluation of heart failure; lower back problems (anticipated to be ready in the late summer/early fall); post- stroke rehabilitation; screening for Alzheimer's and related dementias; treatment of pressure ulcers in adults; and quality determinants of mammography. Next year, the HHS agency hopes to have ready clinical practice guidelines on chest pain due to unstable angina; cardiac rehabilitation services; anxiety and panic disorders in primary care; and smoking prevention and cessation. The agency recently released its fifth guideline, which covers depression in the primary care setting ("The Pink Sheet" April 19, p. 8).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel